Recursion Pharmaceuticals Inc Financial Flexibility Index
Recursion Pharmaceuticals Inc financial flexibility index. Recursion Pharmaceuticals Inc (RXRX) has a Financial Flexibility Index of -0.35x as of June 2026. Free cash flow of $-103.99 Million (operating CF $-105.95 Million minus capex $1.96 Million) represents 0% of total liabilities ($297.67 Million). See RXRX cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Recursion Pharmaceuticals Inc (2019–2025)
Financial flexibility index of Recursion Pharmaceuticals Inc from 2019 to 2025. Historical Financial Flexibility Index trend for Recursion Pharmaceuticals Inc across 7 annual periods. Explore Recursion Pharmaceuticals Inc (RXRX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Recursion Pharmaceuticals Inc Financial Flexibility Index by Year (2019–2025)
Recursion Pharmaceuticals Inc financial flexibility index by year from 2019 to 2025. Year-by-year free cash flow to debt coverage for Recursion Pharmaceuticals Inc. For the full cash flow conversion analysis, see Recursion Pharmaceuticals Inc operating cash flow efficiency.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.06x | $-365.34 Million | $-371.81 Million | $343.26 Million | ▼ -27.5% |
| 2024 | -0.83x | $-345.48 Million | $-359.17 Million | $413.82 Million | ▲ +42.4% |
| 2023 | -1.45x | $-275.82 Million | $-287.78 Million | $190.26 Million | ▼ -576.7% |
| 2022 | -0.21x | $-46.16 Million | $-83.52 Million | $215.48 Million | ▲ +87.8% |
| 2021 | -1.76x | $-118.82 Million | $-158.61 Million | $67.41 Million | ▼ -2201.7% |
| 2020 | -0.08x | $-38.66 Million | $-45.40 Million | $504.87 Million | ▲ +67.5% |
| 2019 | -0.24x | $-53.13 Million | $-57.04 Million | $225.70 Million | — |